These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

629 related articles for article (PubMed ID: 25879723)

  • 1. Vascular endothelial growth factor blockade alters magnetic resonance imaging biomarkers of vascular function and decreases barrier permeability in a rat model of lung cancer brain metastasis.
    Pishko GL; Muldoon LL; Pagel MA; Schwartz DL; Neuwelt EA
    Fluids Barriers CNS; 2015 Feb; 12():5. PubMed ID: 25879723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dynamic magnetic resonance imaging assessment of vascular targeting agent effects in rat intracerebral tumor models.
    Muldoon LL; Gahramanov S; Li X; Marshall DJ; Kraemer DF; Neuwelt EA
    Neuro Oncol; 2011 Jan; 13(1):51-60. PubMed ID: 21123368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative MRI study of the permeability of peritumoral brain edema in lung cancer patients with brain metastases.
    Wang D; Wang ML; Li YH
    Brain Res; 2017 Aug; 1669():126-130. PubMed ID: 28633995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bevacizumab Prevents Brain Metastases Formation in Lung Adenocarcinoma.
    Ilhan-Mutlu A; Osswald M; Liao Y; Gömmel M; Reck M; Miles D; Mariani P; Gianni L; Lutiger B; Nendel V; Srock S; Perez-Moreno P; Thorsen F; von Baumgarten L; Preusser M; Wick W; Winkler F
    Mol Cancer Ther; 2016 Apr; 15(4):702-10. PubMed ID: 26809491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the Response of Intracranial Xenografts to VEGF Signaling Inhibition Using Multiparametric MRI.
    Boult JKR; Box G; Vinci M; Perryman L; Eccles SA; Jones C; Robinson SP
    Neoplasia; 2017 Sep; 19(9):684-694. PubMed ID: 28780387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of tumor oxygenation and its impact on treatment response in bevacizumab-treated recurrent glioblastoma.
    Bonekamp D; Mouridsen K; Radbruch A; Kurz FT; Eidel O; Wick A; Schlemmer HP; Wick W; Bendszus M; Østergaard L; Kickingereder P
    J Cereb Blood Flow Metab; 2017 Feb; 37(2):485-494. PubMed ID: 26861817
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bevacizumab suppresses the growth of established non-small-cell lung cancer brain metastases in a hematogenous brain metastasis model.
    Masuda C; Sugimoto M; Wakita D; Monnai M; Ishimaru C; Nakamura R; Kinoshita M; Yorozu K; Kurasawa M; Kondoh O; Yamamoto K
    Clin Exp Metastasis; 2020 Feb; 37(1):199-207. PubMed ID: 31768815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential expression of vascular endothelial growth factor A, its receptors VEGFR-1, -2, and -3 and co-receptors neuropilin-1 and -2 does not predict bevacizumab response in human astrocytomas.
    Baumgarten P; Blank AE; Franz K; Hattingen E; Dunst M; Zeiner P; Hoffmann K; Bähr O; Mäder L; Goeppert B; Machein M; Seifert V; Steinbach JP; Plate KH; Harter PN; Mittelbronn M
    Neuro Oncol; 2016 Feb; 18(2):173-83. PubMed ID: 26627848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual inhibition of PFKFB3 and VEGF normalizes tumor vasculature, reduces lactate production, and improves chemotherapy in glioblastoma: insights from protein expression profiling and MRI.
    Zhang J; Xue W; Xu K; Yi L; Guo Y; Xie T; Tong H; Zhou B; Wang S; Li Q; Liu H; Chen X; Fang J; Zhang W
    Theranostics; 2020; 10(16):7245-7259. PubMed ID: 32641990
    [No Abstract]   [Full Text] [Related]  

  • 10. A pilot study to determine the timing and effect of bevacizumab on vascular normalization of metastatic brain tumors in breast cancer.
    Chen BB; Lu YS; Lin CH; Chen WW; Wu PF; Hsu CY; Yu CW; Wei SY; Cheng AL; Shih TT
    BMC Cancer; 2016 Jul; 16():466. PubMed ID: 27412562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation.
    Yano S; Herbst RS; Shinohara H; Knighton B; Bucana CD; Killion JJ; Wood J; Fidler IJ
    Clin Cancer Res; 2000 Mar; 6(3):957-65. PubMed ID: 10741721
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute tumour response to a bispecific Ang-2-VEGF-A antibody: insights from multiparametric MRI and gene expression profiling.
    Baker LCJ; Boult JKR; Thomas M; Koehler A; Nayak T; Tessier J; Ooi CH; Birzele F; Belousov A; Zajac M; Horn C; LeFave C; Robinson SP
    Br J Cancer; 2016 Sep; 115(6):691-702. PubMed ID: 27529514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. VEGF-121 plasma level as biomarker for response to anti-angiogenetic therapy in recurrent glioblastoma.
    Martini M; de Pascalis I; D'Alessandris QG; Fiorentino V; Pierconti F; Marei HE; Ricci-Vitiani L; Pallini R; Larocca LM
    BMC Cancer; 2018 May; 18(1):553. PubMed ID: 29747600
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer.
    Heist RS; Duda DG; Sahani DV; Ancukiewicz M; Fidias P; Sequist LV; Temel JS; Shaw AT; Pennell NA; Neal JW; Gandhi L; Lynch TJ; Engelman JA; Jain RK
    Proc Natl Acad Sci U S A; 2015 Feb; 112(5):1547-52. PubMed ID: 25605928
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased Antiangiogenic Effect by Blocking CCL2-dependent Macrophages in a Rodent Glioblastoma Model: Correlation Study with Dynamic Susceptibility Contrast Perfusion MRI.
    Cho HR; Kumari N; Thi Vu H; Kim H; Park CK; Choi SH
    Sci Rep; 2019 Jul; 9(1):11085. PubMed ID: 31366997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor growth modulation by sense and antisense vascular endothelial growth factor gene expression: effects on angiogenesis, vascular permeability, blood volume, blood flow, fluorodeoxyglucose uptake, and proliferation of human melanoma intracerebral xenografts.
    Oku T; Tjuvajev JG; Miyagawa T; Sasajima T; Joshi A; Joshi R; Finn R; Claffey KP; Blasberg RG
    Cancer Res; 1998 Sep; 58(18):4185-92. PubMed ID: 9751633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of bevacizumab, a humanized monoclonal antibody to vascular endothelial growth factor, on peritoneal metastasis of MNK-45P human gastric cancer in mice.
    Ninomiya S; Inomata M; Tajima M; Ali AT; Ueda Y; Shiraishi N; Kitano S
    J Surg Res; 2009 Jun; 154(2):196-202. PubMed ID: 19329124
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of a novel macromolecular cascade-polymer contrast medium for dynamic contrast-enhanced MRI monitoring of antiangiogenic bevacizumab therapy in a human melanoma model.
    Cyran CC; Fu Y; Rogut V; Chaopathomkul B; Wendland MF; Shames DM; Brasch RC
    Acad Radiol; 2013 Oct; 20(10):1256-63. PubMed ID: 24029057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decrease in tumor apparent permeability-surface area product to a MRI macromolecular contrast medium following angiogenesis inhibition with correlations to cytotoxic drug accumulation.
    Daldrup-Link HE; Okuhata Y; Wolfe A; Srivastav S; Øie S; Ferrara N; Cohen RL; Shames DM; Brasch RC
    Microcirculation; 2004; 11(5):387-96. PubMed ID: 15280064
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myoinositol as a Biomarker in Recurrent Glioblastoma Treated with Bevacizumab: A 1H-Magnetic Resonance Spectroscopy Study.
    Steidl E; Pilatus U; Hattingen E; Steinbach JP; Zanella F; Ronellenfitsch MW; Bähr O
    PLoS One; 2016; 11(12):e0168113. PubMed ID: 28033329
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.